André Schmidt
Dr. André Schmidt, researcher in the Department of Psychiatry at the University of Basel
Data updated
Research Footprint
André Schmidt appears in 8 tracked papers (2012–2018), most studied alongside Psilocybin, LSD and MDMA, across Neuroimaging & Brain Measures, Healthy Volunteers and Depressive Disorders.
Most-cited paper: Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors (296 citations).
Frequent co-authors: Ulrich Schmidt, Patrick Dolder and Erich Seifritz.
Background & Research
André Schmidt is a psychiatrist and neuroscientist associated with the University of Basel’s Department of Psychiatry and earlier work at the University of Basel/University Hospital Basel in neuropsychiatry and brain imaging. His research has focused on psychopharmacology, fMRI, psychosis, and the acute neural effects of serotonergic psychedelics such as LSD and psilocybin. He has also been recognized for his early-career contributions to biological psychiatry and schizophrenia research.
Key Impact
He is a neuropsychiatry researcher whose work helped define acute LSD and psilocybin effects on brain connectivity, emotion processing, and hallucinations in healthy volunteers.
Collaboration Network
15 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations André Schmidt is associated with.
University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →University Psychiatric Clinics Basel
hospitalThe University Psychiatric Clinics Basel (Universitäre Psychiatrische Kliniken Basel, UPK) is a leading psychiatric hospital in Switzerland affiliated with the University of Basel. UPK Basel provides comprehensive inpatient and outpatient psychiatric care and conducts internationally recognized research in psychopharmacology, consciousness studies, and psychedelic-assisted therapy.
View stakeholder →